NASDAQ: KOD · Life Sciences · 8 alerts · CIK 1468748
Share price
$100.73Close, Nov 16
Market cap
$6.59B
Shares outstanding
65.4MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kodiak Sciences Inc. filings on SEC EDGAR ↗
Kodiak Sciences Inc. reported a net loss of $190.0 million for the first nine months of 2026, compared to $173.2 million in the prior year period, driven primarily by increased research and development expenses. The company's cash position decreased significantly to $88.7 million as of September 30, 2026, and management indicated a need to raise additional capital to maintain operations and continue its clinical development programs.
Kodiak Sciences reported Q3 2026 financial results and provided updates on its late-stage retinal pipeline, including positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted. The company plans to submit a multi-indication BLA for Zenkuda by the end of 2026 and expects pivotal data for KSI-101 in December 2026.
“We believe Kodiak stands apart in retina, with three late-stage assets that together give us the opportunity to build a leading retinal medicines company.”
Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
“Looking ahead, we expect to announce the first Phase 3 KSI-101 results in December and, if successful, plan to file a BLA for KSI-101 in the second quarter of 2027. We are also on track to submit the multi-indication BLA for Zenkuda by year end, supported by five successful Phase 3 studies.”
Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
Kodiak Sciences Director Baker Bros. Advisors LP Buys $24.3M of Stock
Baker Bros. Advisors LP, Director, bought 247,090 shares of Kodiak Sciences Inc. at $98.51 a share, worth $24.3M in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 20,424,859 (+0.4%).
Kodiak Sciences CFO John A. Borgeson Sells $2.69M of Stock
John A. Borgeson, CFO, sold 29,900 shares of Kodiak Sciences Inc. at $87.67 to $93.71 a share (average $89.99) in 7 transactions, worth $2.69M in total on Oct 21, 2026. Shares held after the trade: 212,030 (-0.9%).
Kodiak Sciences Director Baker Bros. Advisors LP Buys $63.4M of Stock
Baker Bros. Advisors LP, Director, bought 715,508 shares of Kodiak Sciences Inc. at $84.24 to $89.86 a share (average $88.59) in 21 transactions, worth $63.4M in total between Sep 28, 2026 and Sep 29, 2026. Shares held after the trade: 19,772,333 (+0.5%).
Kodiak Sciences Director Baker Bros. Advisors LP Buys $34.9M of Stock
Baker Bros. Advisors LP, Director, bought 418,105 shares of Kodiak Sciences Inc. at $79.40 to $85.97 a share (average $83.58) in 26 transactions, worth $34.9M in total on Sep 28, 2026. Shares held after the trade: 19,153,010 (+0.0%).
Kodiak Sciences Director Baker Bros. Advisors LP Buys $58.6M of Stock
Baker Bros. Advisors LP, Director, bought 807,840 shares of Kodiak Sciences Inc. at $61.21 to $78.57 a share (average $72.57) in 30 transactions, worth $58.6M in total on Sep 28, 2026. Shares held after the trade: 18,435,276 (+0.0%).
Kodiak Sciences announced that its Phase 3 DAYBREAK study in wet age-related macular degeneration (wAMD) met its primary endpoints for both Zenkuda and tabirafusp-ted. Both drugs demonstrated non-inferiority in vision gains compared to aflibercept, with Zenkuda showing 6-month durability in 54% of patients. The company plans to submit a multi-indication Biologics License Application (BLA) for Zenkuda in the fourth quarter of 2026.